Aardvark Therapeutics to Unblind HERO and OLE Data as FDA Places Full Clinical Hold on ARD-101 Trials

FDA Clinical Hold Shifts Focus to Data Analysis

On May 14, 2026, Aardvark Therapeutics announced the U.S. Food and Drug Administration (FDA) has imposed a full clinical hold on all trials involving their investigational treatment, ARD-101. The hold affects both the Phase 3 HERO trial and the ongoing open-label extension (OLE) study. This move follows a previously initiated voluntary study pause and signals an increased regulatory focus on evaluating both efficacy and patient safety in this rare disease program.

Company to Unblind Data: 87 Patients Dosed Across Trials

In response to the FDA’s action, Aardvark will unblind clinical data collected so far—covering 68 patients in the randomized HERO trial and 19 in the OLE extension. This review aims to present a complete picture of ARD-101’s performance in treating hyperphagia associated with Prader-Willi Syndrome (PWS). Unblinding the data midstream is a strategic move; it allows Aardvark and regulators to weigh the risk-benefit profile of the drug and determine the best path forward.

Financial Resources Support Operations into Mid-2027

Aardvark reported $91.2 million in cash, cash equivalents, and short-term investments as of March 31, 2026. According to management, this strong cash position is expected to fund operations through mid-2027, providing the company with runway to navigate the regulatory process and any required follow-up studies.

Strategic Focus: Engaging with FDA While Prioritizing Patient Safety

CEO Tien Lee emphasized ongoing engagement with the FDA, stating that "Patient safety will always be the highest priority for us." While the company remains committed to the Prader-Willi Syndrome community, the immediate priority is collaborating with regulators and comprehensively analyzing the clinical data. The outcome of this process will heavily influence the future of the ARD-101 program, including potential resumption or redesign of clinical trials.

ARD-101: Addressing Unmet Needs in PWS

ARD-101 is a small-molecule, oral drug designed to reduce excessive hunger by activating specific neural pathways. While it holds promise for patients with PWS—a community with limited treatment options—uncertainties remain regarding its benefit-risk balance. The unblinding and analysis of the HERO and OLE trial data will be closely watched as the next big step for this program and for rare disease drug development more broadly.

Key Takeaway for Stakeholders

This shift in strategy highlights the tension between regulatory oversight and innovation in rare disease biopharma. Investors and patient advocates alike will want to monitor updates on Aardvark’s engagement with the FDA and the eventual outcomes from the unblinded clinical data. The next few months could prove decisive in determining whether ARD-101 will ultimately advance as a viable therapy for Prader-Willi Syndrome.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI